Italia markets closed

Dow Jones
38.692,65
+103,49(+0,27%)
Nasdaq
17.804,38
+115,49(+0,65%)
Nikkei 225
38.102,44
-712,12(-1,83%)
EUR/USD
1,0727
+0,0018(+0,17%)
Bitcoin EUR
61.535,75
-532,62(-0,86%)
CMC Crypto 200
1.374,69
-13,48(-0,97%)

NBIX Mar 2025 145.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

17,85

0,00

(0,00%)

In data: 12:16PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat